GSK’s (GSK) Buy Rating Reiterated at Jefferies Financial Group
by Mitch Edgeman · The Markets DailyGSK (LON:GSK – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Financial Group in a research report issued on Thursday,London Stock Exchange reports. They presently have a GBX 2,450 price target on the stock. Jefferies Financial Group’s target price indicates a potential upside of 14.27% from the stock’s previous close.
Several other equities analysts have also recently issued reports on GSK. Berenberg Bank reiterated a “hold” rating and issued a GBX 2,000 price target on shares of GSK in a report on Thursday, March 26th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. UBS Group restated a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Finally, Citigroup upped their target price on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of GBX 2,016.43.
Check Out Our Latest Research Report on GSK
GSK Trading Up 1.8%
GSK stock traded up GBX 37 during trading on Thursday, hitting GBX 2,144. The company had a trading volume of 6,023,037 shares, compared to its average volume of 9,704,467. The firm has a 50-day moving average price of GBX 2,057.08 and a 200-day moving average price of GBX 1,845.80. GSK has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 2,282. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 108.20. The stock has a market cap of £86.00 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 1.24 and a beta of 0.32.
GSK (LON:GSK – Get Free Report) last announced its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. As a group, analysts predict that GSK will post 175.980975 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Anne Beal purchased 196 shares of the stock in a transaction dated Friday, March 20th. The stock was bought at an average cost of GBX 5,179 per share, with a total value of £10,150.84. Also, insider Luke Miels sold 15,579 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total transaction of £336,506.40. Insiders have purchased a total of 11,447 shares of company stock valued at $24,273,097 over the last 90 days. 0.26% of the stock is owned by corporate insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.